CN115867352A - 抗α4β7抗体 - Google Patents

抗α4β7抗体 Download PDF

Info

Publication number
CN115867352A
CN115867352A CN202180049613.2A CN202180049613A CN115867352A CN 115867352 A CN115867352 A CN 115867352A CN 202180049613 A CN202180049613 A CN 202180049613A CN 115867352 A CN115867352 A CN 115867352A
Authority
CN
China
Prior art keywords
ser
val
gly
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049613.2A
Other languages
English (en)
Chinese (zh)
Inventor
闵静
T·(I-C)·吴
L·贝纳图尔
J·比斯比
T·代克蒂尔
董枫
A·小埃尔南德斯
P·克里希南
陆良军
F·门萨
R·米勒
G·萨胡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of CN115867352A publication Critical patent/CN115867352A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CN202180049613.2A 2020-07-16 2021-07-16 抗α4β7抗体 Pending CN115867352A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052933P 2020-07-16 2020-07-16
US63/052933 2020-07-16
PCT/US2021/070898 WO2022016198A1 (en) 2020-07-16 2021-07-16 Anti-αlpha-4-βeta-7 antibodies

Publications (1)

Publication Number Publication Date
CN115867352A true CN115867352A (zh) 2023-03-28

Family

ID=77338969

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049613.2A Pending CN115867352A (zh) 2020-07-16 2021-07-16 抗α4β7抗体

Country Status (15)

Country Link
US (2) US11639390B2 (enExample)
EP (1) EP4182349A1 (enExample)
JP (2) JP7408008B2 (enExample)
KR (1) KR20230038728A (enExample)
CN (1) CN115867352A (enExample)
AR (1) AR122983A1 (enExample)
AU (1) AU2021307468A1 (enExample)
CA (1) CA3188739A1 (enExample)
CO (1) CO2023001066A2 (enExample)
IL (1) IL299767A (enExample)
MX (1) MX2023000732A (enExample)
TW (1) TWI889871B (enExample)
UY (1) UY39327A (enExample)
WO (1) WO2022016198A1 (enExample)
ZA (1) ZA202300222B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
WO2025038861A1 (en) * 2023-08-15 2025-02-20 Abbvie Inc. Methods of treating human immunodeficiency virus (hiv) disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AP2015008338A0 (en) * 2012-09-26 2015-04-30 Kflp Biotech Llc Compounds for the treatment and prevention of retroviral infections
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life

Also Published As

Publication number Publication date
MX2023000732A (es) 2023-02-13
CA3188739A1 (en) 2022-01-20
JP7765447B2 (ja) 2025-11-06
UY39327A (es) 2022-02-25
BR112023000718A2 (pt) 2023-02-07
KR20230038728A (ko) 2023-03-21
EP4182349A1 (en) 2023-05-24
ZA202300222B (en) 2023-09-27
CO2023001066A2 (es) 2023-02-06
JP7408008B2 (ja) 2024-01-04
US20220017624A1 (en) 2022-01-20
US11639390B2 (en) 2023-05-02
TWI889871B (zh) 2025-07-11
TW202216781A (zh) 2022-05-01
AU2021307468A1 (en) 2023-02-02
JP2024037932A (ja) 2024-03-19
AR122983A1 (es) 2022-10-19
IL299767A (en) 2023-03-01
WO2022016198A1 (en) 2022-01-20
US20260062488A1 (en) 2026-03-05
JP2023535556A (ja) 2023-08-18

Similar Documents

Publication Publication Date Title
CN108883173B (zh) 抗体和其使用方法
JP6867955B2 (ja) 抗ｏｘ４０抗体及びその使用方法
WO2017025051A1 (en) Novel anti-pd-1 antibodies
WO2017024515A1 (en) Novel anti-pd-1 antibodies
TW201803905A (zh) 用於免疫腫瘤學之多重專一性抗體
TW201639880A (zh) 針對ｒｏｒ１之特異性抗體及嵌合抗原受體
CN113056487A (zh) 抗tnfr2抗体及其用途
US20260062488A1 (en) Anti-alpha-4-beta-7 antibodies
JP2022516140A (ja) 白血球免疫グロブリン様受容体２中和抗体
CN114901689A (zh) 用ilt-2抑制剂治疗癌症
JP2025505650A (ja) 抗イディオタイプ抗体分子及びその使用
KR20240161970A (ko) 항-par2 항체
WO2023077172A2 (en) Novel anti-lilrb2 antibodies and derivative products
BR122024013054A2 (pt) Anticorpo monoclonal humano anti-alfa-4--beta-7
BR112023000718B1 (pt) Anticorpo monoclonal anti-alfa-4-beta-7 humano
HK40118198A (en) Novel anti-pd-1 antibodies
TW202444754A (zh) 抗體
HK40107549A (zh) 抗c-c基序趋化因子受体8(ccr8)抗体以及使用方法
CN116685603A (zh) B和t淋巴细胞衰减因子（btla）调节剂及其使用方法
CN118240092A (zh) 一种抗pd-l1和tigit双特异性抗体融合蛋白及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination